XENE Company Profile and Key Details

Q: Who are the executives of XENE?

Ms. Sherry AulinChief Financial OfficerMs. Shelley McCloskey B.A.Executive Vice President of HRMs. Sheila M. Grant M.B.A., M.Sc., MBAExecutive Vice President of R&D OperationsMr. Ian C. Mortimer C.M.A., CPA, CMA, CPA, M.B.A., MBAPres, Chief Executive Officer & DirectorDr. Robin P. Sherrington Ph.D.Executive Vice President of Strategy & InnovationDr. James R. Empfield Ph.D.Executive Vice President of Drug DiscoveryMs. Jodi Regts M.B.A., B.A., MBAVice President of Corporation Affairs & Investor RelationsDr. Christopher E. Von Seggern M.B.A., M.P.H., M.P.H. M.B.A, Ph.D.Chief Commercial OfficerMs. Andrea DiFabio J.D.Chief Legal Officer & Corporation Sec.Dr. Christopher John Kenney M.D.Chief Medical OfficerMr. Ian C. Mortimer C.M.A., C.P.A., CMA, CPA, M.B.A., MBAPres, Chief Executive Officer & Director

NASDAQ : XENE

Xenon Pharmaceuticals

$67.72

-1.2-1.74%

At Close 4:00 PM

59.27

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Xenon Pharmaceuticals Inc. (XENE) stock declined over -1.74%, trading at $67.72 on NASDAQ, down from the previous close of $68.92. The stock opened at $67.79, fluctuating between $65.53 and $67.86 in the recent session.

Stock Snapshot

68.92

Prev. Close

5.35B

Market Cap

65.5301

Day Low

-14.41

P/E Ratio

-4.7

EPS (TTM)

-2.13

Cash Flow per Share

67.79

Open

78.95M

Number of Shares

67.855

Day High

92.85%

Free Float in %

13.26

Book Value

1.53M

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Jul 13, 2026	67.79	67.87	65.53	67.72	1.53M
Jul 10, 2026	70.57	71.03	67.21	68.92	1.54M
Jul 09, 2026	70.47	72.66	69.15	70.96	2.59M
Jul 08, 2026	63.08	70.84	62.90	69.95	4.75M
Jul 07, 2026	61.10	63.97	60.27	63.37	1.44M
Jul 06, 2026	60.78	61.17	59.62	60.54	1.73M
Jul 02, 2026	60.33	61.63	60.00	60.96	1.46M
Jul 01, 2026	59.95	60.88	59.61	60.30	1.27M
Jun 30, 2026	60.09	60.53	59.56	60.36	1.25M
Jun 29, 2026	59.03	60.16	58.13	60.13	1.69M
Jun 26, 2026	56.97	60.32	56.80	59.74	8.84M
Jun 25, 2026	55.40	57.14	55.28	56.78	1.11M
Jun 24, 2026	54.61	56.55	54.61	55.58	1.43M
Jun 23, 2026	54.62	55.47	54.12	54.61	1.5M
Jun 22, 2026	52.91	55.59	52.91	54.79	1.86M
Jun 18, 2026	54.09	54.73	52.53	52.91	2.37M
Jun 17, 2026	52.26	53.83	52.11	53.20	1.16M
Jun 16, 2026	52.49	52.68	51.54	51.99	709.93K
Jun 15, 2026	52.14	52.75	51.67	52.40	1.17M
Jun 12, 2026	52.02	53.07	52.01	52.10	704.21K

Contact Details

Burnaby, BC V5G 4W8

Canada

https://www.xenon-pharma.com 160 448 43300

About Company

Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and advancing innovative treatments for individuals living with neurological disorders. The company operates primarily from its headquarters in Burnaby, Canada. Its robust clinical pipeline showcases several promising candidates: XEN496, an activator of Kv7 potassium channels, is currently in Phase III clinical trials for KCNQ2 developmental and epileptic encephalopathy. Another Kv7 potassium channel activator, XEN1101, is progressing through Phase II trials, targeting epilepsy and a range of other neurological conditions. The portfolio also includes NBI-921352, a selective inhibitor of the Nav1.6 sodium channel, which is undergoing Phase II clinical evaluation for SCN8A developmental and epileptic encephalopathy, alongside investigations for adult focal epilepsy and other potential indications. Furthermore, XEN007, a central nervous system-acting calcium channel modulator, is also in Phase II development. Beyond its internal development, Xenon Pharmaceuticals has established strategic collaborations. This includes a licensing and development agreement with Neurocrine Biosciences, Inc. focused on epilepsy treatments, and a partnership with Flexion Therapeutics, Inc. to advance PCRX301 (also known as XEN402), a Nav1.7 inhibitor, for post-operative pain management. Established in 1996, the company continues its mission to address significant unmet medical needs in neurology.

Stock Peers

ARGX

-1.37-0.16%

argenx SE$876.25 REGN

-1.43-0.22%

Regeneron Pharmaceuticals, Inc.$663.09 UTHR

-11.49-2.10%

United Therapeutics Corporation$535.57 MDGL

-5.7-1.06%

Madrigal Pharmaceuticals, Inc.$531.00 VRTX

-5.14-1.06%

Vertex Pharmaceuticals Incorporated$480.25 KRYS

-2.37-0.65%

Krystal Biotech, Inc.$363.44 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 PRAX

-10.43-3.21%

Praxis Precision Medicines, Inc.$314.56 LGND

-6.99-2.21%

Ligand Pharmaceuticals Incorporated$309.25 ONC

5.26001+1.76%

BeOne Medicines AG$303.96

Company Overview

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) closed at $67.72 USD, losing -$1.20 (-1.74%) from the previous close of $68.92. The stock is currently mid-range between its 52-week high and low $30.00 and $72.66. With a market capitalization of about $5.35 billion, Xenon Pharmaceuticals Inc. is classified as a mid-cap and shows lower-than-market volatility (beta ~0.61). Key stats such as the average daily volume over the past year has been around 1.42 million shares, in line with its 52-week average. Headquartered in Burnaby, BC, Xenon Pharmaceuticals Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Andrea DiFabio, the company employs approximately 316 people and listed since November 05, 2014. Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and advancing innovative treatments for individuals living with neurological disorders.

Technical Performance

XENE has shown mixed momentum, gaining 0.63% over the past week and -0.34% over the past quarter, though year-to-date performance is down -7.43%. Short-term trend indicators are mixed aligned (SMA20 6.11%, SMA50 5.59%, SMA200 18.27%). The stock’s 14-day RSI is 62.92 (firm momentum), while the ATR of 1.61 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -3.61% below its high and over 67.99% above its low. Average 10-day trading volume of 2.26 million shares is significantly above the 3-month average of 1.42 million, indicating heightened recent market interest.

Valuation Metrics

Xenon Pharmaceuticals Inc. trades at a P/E ratio of -14.31, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 4.39 trading at moderately above to book value. The P/FCF stands at -17.28, also below market averages.

Dividend & Fair Value

Xenon Pharmaceuticals Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $2.34. This means the shares are trading above this model’s fair value.

Earnings & Analyst Outlook

Xenon Pharmaceuticals Inc. generated EPS of -$3.88 over the past year. Five-year average earnings growth is -14.28%. Wall Street analysts project EPS growth of -13.97% annually over the next five years. The latest quarter delivered EPS of -$1.17. The next quarter is forecast at -$1.19. Next year's EPS is expected at -$17.64. Analyst sentiment is bullish. Analyst rating data shows there are 18 Strong Buy ratings, 8 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $97.00 to $43.00. The high target offers 43.24% upside. The low target suggests -36.5% downside. The mean target is $63.96. This offers -5.55% upside. Xenon Pharmaceuticals Inc. earnings surprise history is a mixed track record. The quarter that ended May 07, 2026, missed forecasts by 0.0%. The prior quarter beat by 9.17%. Over the last six quarters, Apple has recorded several small beats. These include -5.62% in February 27, 2025.

Shareholding & Insider Activity

Xenon Pharmaceuticals Inc. has 77.11 million shares outstanding. The public float is 71.60 million shares, elevated short interest at 9.99% of float. This equals 6.91 million shares. The short ratio is 7.33 days. Institutional investors hold 111.24% of the float. Insiders own 0.13%. BVF PARTNERS L P/IL holds 1.08 million shares, Hayden Michael R has 161.19 thousand shares and HOLLER FRANK A has 143.65 thousand shares. Over the past six months, insider transactions show net selling. They sold 90.87 thousand shares across 9 transactions.

Financial & Profitability Overview

Over the trailing twelve months, Xenon Pharmaceuticals has not generated any revenue. Returns are negative, with ROA at -18.90% and ROE at -19.66%.
On valuation metrics, Xenon Pharmaceuticals trades at a P/E of -14.31, P/S of 0.00 and P/B of 4.39. The current ratio is 27.79 and quick ratio is 27.79. Operationally, the company’s inventory turnover is 0.00 and cash conversion cycle is -26.80 days , indicating it collects cash faster than it pays suppliers. Debt-to-equity is 0.01, supported by a cash flow-to-debt ratio of -40.90.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Xenon Pharmaceuticals posted revenue of $0.00, down slightly from $9.43M in the prior quarter. Gross profit was - $3.54M (margin 0.00%). Operating income was - $214.05M (margin 0.0%). Net income was- $182.39M (EPS - $2.73).
The company ended the quarter with $638.08M in cash and short-term investments, a total debt of $10.90M, and net debt of - $137.74M. Total assets were $964.80M, with equity of $927.92M. Financials further reflected weakness, with operating cash flow of - $145.33M, free cash flow of - $150.94M, and capital expenditures of - $5.62M.

Price Forecast & Outlook

Our AI price prediction model suggests that Xenon Pharmaceuticals Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 15.7%, with price expected at $78.35 by July 27, 2026, within a range of $76.42 to $80.36 3-Month Outlook: Projected rise of 49.57%, reaching $101.29 by October 08, 2026, with a range of $98.45 to $104.88. 1-Year Outlook: Projected gain of 4.68%, with price at $70.89 by July 13, 2027, within a range of $68.69 to $73.47.

Key Takeaways

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) shares are flat -7.43% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Xenon Pharmaceuticals Inc. trading at a premium to the broader market with a P/E of -14.31. Analyst sentiment is bullish, with the majority of ratings in Overweight territory and a mean price target of $51.81, suggesting -23.49% downside. Our AI forecast model points to short-term strength (15.7% over two weeks), a medium-term rise (49.57% over three months), and a longer-term gain (4.68% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Xenon Pharmaceuticals Inc. (XENE) stock price?

Xenon Pharmaceuticals Inc. (NASDAQ: XENE) stock price is $67.72 in the last trading session. During the trading session, XENE stock reached the peak price of $67.86 while $65.53 was the lowest point it dropped to. The percentage change in XENE stock occurred in the recent session was -1.74% while the dollar amount for the price change in XENE stock was - $1.20.

XENE's industry and sector of operation?

The NASDAQ listed XENE is part of Biotechnology industry that operates in the broader Healthcare sector. Xenon Pharmaceuticals Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of XENE?

Ms. Sherry Aulin
Chief Financial Officer
Ms. Shelley McCloskey B.A.
Executive Vice President of HR
Ms. Sheila M. Grant M.B.A., M.Sc., MBA
Executive Vice President of R&D Operations
Mr. Ian C. Mortimer C.M.A., CPA, CMA, CPA, M.B.A., MBA
Pres, Chief Executive Officer & Director
Dr. Robin P. Sherrington Ph.D.
Executive Vice President of Strategy & Innovation
Dr. James R. Empfield Ph.D.
Executive Vice President of Drug Discovery
Ms. Jodi Regts M.B.A., B.A., MBA
Vice President of Corporation Affairs & Investor Relations
Dr. Christopher E. Von Seggern M.B.A., M.P.H., M.P.H. M.B.A, Ph.D.
Chief Commercial Officer
Ms. Andrea DiFabio J.D.
Chief Legal Officer & Corporation Sec.
Dr. Christopher John Kenney M.D.
Chief Medical Officer
Mr. Ian C. Mortimer C.M.A., C.P.A., CMA, CPA, M.B.A., MBA
Pres, Chief Executive Officer & Director

How XENE did perform over past 52-week?

XENE's closing price is 125.73% higher than its 52-week low of $30.00 where as its distance from 52-week high of $72.66 is -6.8%.

How many employees does XENE have?

Number of XENE employees currently stands at 316.

Link for XENE official website?

Official Website of XENE is: https://www.xenon-pharma.com

How do I contact XENE?

XENE could be contacted at phone 160 448 43300 and can also be accessed through its website. XENE operates from 3650 Gilmore Way, Burnaby, BC V5G 4W8, Canada.

How many shares of XENE are traded daily?

XENE stock volume for the day was 1.53M shares. The average number of XENE shares traded daily for last 3 months was 1.42M.

What is the market cap of XENE currently?

The market value of XENE currently stands at $5.35B with its latest stock price at $67.72 and 78.95M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	316
Beta	0.61
Sales or Revenue	$0.00
5Y Sales Change%	0%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

XENE Company Profile and Key Details

Xenon Pharmaceuticals

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Shareholding & Insider Activity

Dividend & Fair Value

Financial & Profitability Overview

Quarterly Financial Highlights

Company Overview

Earnings & Analyst Outlook

Valuation Metrics

Key Takeaways

Price Forecast & Outlook